GLP-1 Hair Loss: Shedding and When to Seek Care

Hair shedding can occur during GLP-1 treatment and weight loss. It should not automatically be dismissed as temporary, blamed entirely on the drug, or treated by adding a hair-growth medicine without a diagnosis. Weight-loss-related shedding is one possibility; nutritional problems, pattern hair loss and other conditions can also matter.

The useful next step is to review the timing, pattern of loss, nutrition and medication history with the clinician managing treatment or a dermatologist. This guide concerns adults. Sources were checked October 1, 2026.

What do the medication trials report?#

Hair loss appears in the current US labeling for both Wegovy and Zepbound. The reported percentages describe particular studies and formulations, not the chance that every person taking any GLP-1 product will lose hair.

Wegovy (semaglutide): the June 2026 prescribing information reports hair loss in 3.3% of adults receiving the 2.4 mg injection versus 1% receiving placebo in pooled studies 2, 3 and 4. It separately reports 5.8% with the 7.2 mg injection, 3.3% with 2.4 mg and 1% with placebo in the higher-dose clinical trials. The label associates these events with weight reduction. These figures should not be transferred to Ozempic, oral formulations or an unapproved research vial. Wegovy prescribing information, section 6.1

Zepbound (tirzepatide): pooled weight-reduction studies 1 and 2 reported hair loss in 5%, 4% and 5% of the 5 mg, 10 mg and 15 mg groups, respectively, versus 1% with placebo. The label also reports higher rates in women than men and associates the events with weight reduction. It does not identify the cause of an individual patient's shedding. Zepbound prescribing information, section 6.1

These were different study populations and regimens. Comparing the percentages across labels cannot establish which medicine is safer for your hair.

Is it telogen effluvium—or something else?#

Telogen effluvium is excessive shedding that can follow a significant physical or emotional stressor, including substantial weight loss. It often becomes noticeable months after the event, so the day you first see extra hair in the shower may not identify the trigger.

The American Academy of Dermatology explains that shedding can settle as the body adjusts, with fullness often returning over six to nine months. Ongoing stressors can prolong it, and some people have both excessive shedding and another form of hair loss. That general timeline is not a promise that every GLP-1-associated episode will resolve by a particular month. AAD: shedding versus hair loss

For GLP-1 treatment specifically, the AAD's current guidance describes rapid weight change and reduced nutritional intake as possible contributors while acknowledging uncertainty about direct medication effects. “It is definitely only the weight loss” goes beyond that evidence.

A new diagnosis of shedding also does not rule out pre-existing pattern hair loss. A progressively widening part, receding hairline, patches, scalp symptoms or continued deterioration gives the clinician information that a simple shed count cannot.

Prepare a useful review#

Bring a short timeline rather than trying to diagnose the cause from a single photograph:

• When the medicine started and when its dose changed.
• When weight loss began, roughly how it progressed, and when shedding became noticeable.
• Whether you can eat normally, including any persistent nausea, vomiting or major dietary restriction.
• Recent illness, surgery, other medication changes, and previous hair or scalp problems.
• Whether the change is diffuse, concentrated in a pattern, patchy, painful or accompanied by irritation.

A few photographs under similar lighting can help describe change. They cannot distinguish every cause. Ask whether an examination or targeted tests for a suspected nutritional, hormonal or other medical problem are appropriate. AAD describes diagnosis as a history and scalp examination, with blood tests or biopsy when indicated—not a universal laboratory panel for everyone. AAD diagnosis and treatment

Seek assessment for sudden, patchy, painful or persistent loss rather than waiting for a supposed normal shedding deadline. If vomiting or restricted intake makes it difficult to maintain nutrition or hydration, contact the prescribing team promptly.

Should you stop treatment, add minoxidil or take supplements?#

Discuss a medication change with the prescriber. The reason for treatment, its benefits, the hair diagnosis and other adverse effects all matter. Shedding alone does not supply a universal instruction to stop, continue indefinitely or change the dose yourself.

Minoxidil may be discussed for an appropriate diagnosis, but evidence for pattern hair loss does not establish that every episode of weight-loss-related shedding needs it. Our oral versus topical minoxidil guide explains the route-specific evidence and risks; it is not a treatment plan for undiagnosed shedding.

Supplements are also diagnosis-dependent. AAD recommends biotin, iron or zinc supplementation when testing identifies a relevant deficiency and warns that excess can be harmful. Bring your existing supplements to the review instead of adding several overlapping “hair” products. AAD treatment guidance

If a hair treatment is prescribed, agree on how and when to review it. The treatment-timing guide separates trial endpoints and routine reviews from symptoms that need earlier attention. The goal is to identify what is happening and choose an appropriate response, not to assume that every new shed needs another product.